Skip to main content

Table 2 Number of evaluable patients (%) with stable disease or better response* by MIPI risk category [13,14]

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

 

n/N (%) [n]

Treatment

Low risk

Intermediate risk

High risk

Temsirolimus 175/75 mg

9/12 (75)

11/18 (61)

8/10 (80)

[5 PR, 4 SD]

[1 CR, 5 PR, 5 SD]

[1 PR, 7 SD]

Temsirolimus 175/25 mg

10/13 (77)

5/15 (33)

5/15 (33)

[2 PR, 8 SD]

[1 PR, 4 SD]

[5 SD]

INV therapy

4/11 (36)

8/20 (40)

0/9 (0)

[4 SD]

[1 CR, 7 SD]

 
  1. *Disease assessment was based on radiographic review by independent radiologists and review of clinical data by independent oncologists; evaluable patients were those with tumor assessment available.
  2. MIPI = Mantle Cell Lymphoma International Prognostic Index; PR = partial response; SD = stable disease ≥8 weeks; CR = complete response; INV = Investigator’s choice.